Giuseppe Michieli#Safety, Tolerability and Pharmacokinetics of Half-Life Extended #SARS-CoV-2 Neutralizing Monoclonal #Antibodies #AZD7442 (#Tixagevimab / #Cilgavimab) in Healthy Adults https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad014/6997870?rss=1
Safety, Tolerability and Pharmacokinetics of Half-Life Extended SARS-CoV-2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab/Cilgavimab) in Healthy Adults
A single 300-mg intramuscular dose of AZD7442 (150-mg each of tixagevimab/cilgavimab) exhibited an approximate 90-day half-life, was well tolerated in a phase 1